



ScienceDirect

Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jval

Comparative-Effectiveness Research/HTA

Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products

Charlotte Desterbecq, MPH, Sandy Tubeuf, PhD

ABSTRACT

Objectives: Climate change and environmental factors have an impact on human health and the ecosystem. The healthcare sector is responsible for substantial environmental pollution. Most healthcare systems rely on economic evaluation to select efficient alternatives. Nevertheless, environmental spillovers of healthcare treatments are rarely considered whether it is from a cost or a health perspective. The objective of this article is to identify economic evaluations of healthcare products and guidelines that have included any environmental dimensions.

Methods: Electronic searches of 3 literature databases (PubMed, Scopus, and EMBASE) and official health agencies guidelines were conducted. Documents were considered eligible if they assessed the environmental spillovers within the economic evaluation of a healthcare product or provided any recommendations on the inclusion of environmental spillovers in the health technology assessment process.

Results: From the 3878 records identified, 62 documents were deemed eligible and 18 were published in 2021 and 2022. The environmental spillovers considered were carbon dioxide (CO₂) emissions, water or energy consumption, and waste disposal. The environmental spillovers were mainly assessed using the lifecycle assessment (LCA) approach while the economic analysis was mostly limited to costs. Only 9 documents, including the guidelines of 2 health agencies presented theoretical and practical ways to include environmental spillovers into the decision-making process.

Conclusions: There is a clear lack of methods on whether environmental spillovers should be included in health economic evaluation and how this should be done. If healthcare systems want to reduce their environment footprint, the development of methodology which integrates environmental dimensions in health technology assessment will be key.

Keywords: economic evaluation, environmental spillovers, health technology assessment, healthcare products.

VALUE HEALTH. 2023; ■(■):■-■

Introduction

Health and the environment are closely related. Research acknowledges the relationship between the onset of diseases; and a combination of individual characteristics and environmental, lifestyle, and socioeconomic factors.¹ Environmental factors such as pollution, climate change or extreme events impact human health and the ecosystem.² These factors lead to an increase in mortality and the incidence of respiratory, cardiovascular, and mental health diseases.³ The World Health Organization considers climate change as “the single biggest health threat facing humanity”² and estimated, in 2018, that it will cause 250 000 premature deaths per year between 2030 and 2050.^{2,4} Rapid and deep actions are therefore required across all the sectors to limit global warming up to 1.5°C and to ensure sustainable health in the long-term.⁵

Healthcare systems have a role to play in this context, as demonstrated by 1 of the 2 major commitments of the COP26 Health Programme: “Sustainable low carbon health systems.”⁶

According to the report of the Lancet Countdown on health and climate change,⁷ 4.9% of the global greenhouse gas emissions were attributable to the healthcare sector. Eckelman and Sherman⁴ estimated that the global greenhouse gas emissions emitted by the US healthcare sector, cause between 123 000 to 381 000 disability adjusted life-years (DALYs) annually. The environmental pollution of the healthcare sector contributes to increased poor health within the population; and contributes to systemic vulnerabilities and inequalities. Such pollution could be called environmental spillovers as spillovers are defined as the desirable or undesirable impacts on costs and outcomes other than those targeted by the intervention.”⁸ In this scoping review, we specifically focus on the undesirable environmental consequences of healthcare technologies.

Economic evaluation, especially health technology assessment (HTA) is key in guiding healthcare decision in most countries worldwide following the gold standard set by the National Institute for Health and Care Excellence.⁹ Economic evaluation “requires a comparison of 2 or more alternative courses of action,

while considering both the input (costs) and output (consequences) associated with each"¹⁰ and "ensures that the value of what is gained from an activity outweighs the value of what is sacrificed."^{11,12} The health gains of healthcare technologies are usually measured using health-related quality of life measures.^{12,13} Nevertheless, if the environmental spillovers of the healthcare sector are responsible for poorer health or thousands of DALYs per year then the global effectiveness of healthcare technologies should not only be limited to the direct health-related quality of life gains but should also include environment-related impacts.

The objective of this review was to identify whether and how environment-related spillovers are considered when healthcare interventions are evaluated or when reimbursement decisions are formulated. Since environmental spillovers of healthcare technologies in economic evaluation is an emerging topic of research we conducted a scoping review to map what already exists.

Methods

Protocol and Registration

The study protocol was developed a priori and was followed throughout the conduct of the scoping review. The protocol was registered with Figshare (<https://doi.org/10.6084/m9.figshare.17185589>) on December 17, 2021.

Search Strategy

Three databases (EMBASE, PubMed and Scopus) were searched using search strategies developed with the help of an expert librarian. We chose to focus on countries from the "Europe of 12" and "G20" countries as they have identified health agencies and are more likely to be formally engaged with increased sustainable healthcare (see Appendix 1 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2023.03.008>). Main search terms included economic evaluation and healthcare systems of countries of interest and were combined with terms related to the environment. The full search strategy is available in Appendix 2 in Supplemental Materials found at <https://doi.org/10.1016/j.jval.2023.03.008>. Authors were contacted by email for full-text article when only the abstract of a conference presentation was available but the article seemed relevant. In addition, websites of the official health agencies of the 27 countries of interest were searched to identify guidelines and any documents where a framework to undertake an economic evaluation in the healthcare sector was provided. Health agencies were also contacted to provide access to guidelines if documents were unavailable on their website. Finally, the reference lists of included studies were reviewed to identify additional eligible references. The searches were undertaken between the June 1, 2021 and the July 15, 2021 and updated on September 6, 2022.

Eligibility Criteria

Eligibility criteria differed for articles identified through electronic databases and institutional documents. Any article identified through searches of the 3 electronic databases were eligible for inclusion if they were published after the year 2000. Documents published before the year 2000 were excluded because of being considered outdated. Documents were eligible if they were available in French or English, related to countries of "EU-12" or "G20," and undertook an economic evaluation along with an environmental evaluation of a healthcare technology or provided recommendations on how to consider environmental impacts of a healthcare product in an economic evaluation. Regarding health agencies, any available guidelines were eligible for inclusion if

they were published after the year 2000 and mentioned environmental assessment as a part of the HTA process. There was no language restriction for the inclusion of reports from the healthcare agencies; a translation software (<https://www.deepl.com/translator>) was used if reports were written in an another language than English or French.

Source of Evidence Screening and Selection

EndNote X9 Software (<https://endnote.com/>) and Rayyan Systems Inc (<https://www.rayyan.ai/>) were used to collate and organize the search results from the 3 databases. On concluding the search of the listed databases, duplicates were removed. The screening and selection process was performed in 2 steps. First, all the references were screened and selected using titles and abstracts only. Second, the full texts of the included citations were retrieved and screened. The selection of documents followed a rigorous two-stage process. Two reviewers (Charlotte Desterbecq and Clément Beghuin) selected relevant documents independently and then, pooled their selection. If reviewers could not decide whether a publication should be included in the review, a third reviewer (Sandy Tubeuf) was asked to address any discrepancies. Guidelines from health agency websites were screened by a fourth reviewer (Roxane Mousset). Documents captured in the database or in list of references that were deemed relevant to the review objective, were used to cross-check the included studies.

Data Extraction


A Microsoft Excel spreadsheet was used to extract and record data from the full-text analysis. Two reviewers (CD and CB) independently completed the data extraction form for a preliminary sample of 10 publications and then compared the relevance of extracted information from the publications. Any discrepancy in extracted data were discussed by both reviewers and resolved by consensus. The documents were then equally distributed between the 2 reviewers; and data extraction forms completed for the remaining, included publications and institutional documents. Extracted data included year of publication, authors' name, publication title, research objective, study design, dataset, country(ies), type of economic evaluation, type of evaluated healthcare product, assessed environment-related elements, and their impacts on the economic evaluation. Regarding institutional documents, the different phases of the HTA process were extracted.

Results

Search Results

A total of 3843 citations were identified from the 3 databases; 729 duplicated citations were removed and 3114 citations were screened. After titles and abstracts screening; 2997 citations were excluded and 117 full text citations were reviewed and 63 were excluded for various reasons. Regarding healthcare agency websites, 27 documents were initially identified and citations searching led to identify 8 additional documents. From these, only 8 documents were deemed eligible for data extraction. The detailed process of articles selection is presented in a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) chart (see Fig. 1).

Overall, a total of 62 documents were included in the scoping review.¹⁴⁻⁷⁵ The included documents jointly considered the environmental and economic dimensions of specific healthcare

Figure 1. Flow diagram describing the selection process of included publications.

technologies by means of case studies, international guidelines, literature reviews, and reflective articles.

Documents Characteristics

The characteristics of each included document are available in Table 1.¹⁴⁻⁷⁸ Documents were published between 2004 and 2022. The majority (96.7%, $n = 60$) were published from year 2009 onwards and 18 (29.1%) were published in years 2021 and 2022 (see Fig. 2).

According to the location mentioned in the document or the location of the corresponding authors, 17 studies were carried out in the UK, 10 in Australia, and 9 in the USA. There were also documents from England (4), Brazil (3), Ireland (3), Italy (3), Germany (2), Canada, (2) Luxembourg (1), The Netherlands (1), South Korea (1), France (1), and Spain (1). Finally, 3 studies were multicountries.

A summary of the assessed healthcare technologies, and for each technology the specified type of environmental spillovers being considered are provided in Table 2. The most investigated environmental spillover was carbon dioxide (CO_2) or CO_2 equivalent emissions (48%) (see Fig. 3).

Among the identified documents, the inclusion of environmental spillovers was undertaken in 2 alternative approaches. We defined the first approach “separate approach” as the environmental and the economic assessments of healthcare products were clearly undertaken independently from each other and the economic evaluation often was only a partial approach where costs only were considered and health gains were fully ignored, this approach included 51 articles. We defined the second approach “integrative approach” as environmental concerns were either directly included in a full economic evaluation or discussed to be integrated as a part of the HTA process, this approach included 11 articles. We presented the results from each of these approaches.

Separate Approach

Among the articles relevant to the separate approach, the different environment-related dimensions were measured as CO_2 or CO_2 equivalent emissions, water or energy consumption and waste generation.

CO_2 or CO_2 equivalent emissions

Around 40% of the included records ($n = 23$) considered CO_2 emissions of healthcare products. In almost 50% of those ($n = 11$), CO_2 emissions were calculated from converted travel distances or mileage savings resulting from the use of healthcare products and expressed as carbon footprint emissions or reductions.^{23,27,28,30,31,40,43,53,56,73,75} Financial costs were estimated as cost savings associated with travel reductions such as estimated petrol and parking costs for the patient²⁷ ($n = 7$), as the costs that the patients could have spent on transport if they had a face-to-face consultation ($n = 1$), or as limited to the direct costs (eg, cost of electricity being used⁵³) of the healthcare products ($n = 2$). In 1 study, a societal perspective including costs to the healthcare system, out-of-pockets costs, and cost of time-off-working were considered⁷⁵

In 3 different articles (4.8%), Maughan et al⁴⁴⁻⁴⁶ compared the costs to the environment of 3 different healthcare products (social prescribing service, long-acting injections, and therapeutic community) with usual care. They converted resource use of the new products including energy consumption, medical materials used, prescribed medications, number of appointments, and staff and patient travels into either carbon footprint or financial cost.

Two studies (3.2%) evaluated the change in healthcare practice: 1 study evaluated the use of low carbon alternatives to Desflurane during anaesthesia¹⁶ and calculated cost savings as CO_2 reductions; while the other study evaluated the implementation of a medical program aiming to limit the prescription of biochemical

Table 1. Summary of the included documents in the review.

Authors and references	Year of publication	Healthcare products	Environment-related dimensions					Economic evaluation	Location
			CO ₂ or CO ₂ eq	Water	Energy	Waste	Other		
Adler et al ¹⁴	2005	Disposable and reusable instruments used for laparoscopic cholecystectomy		X	X	X		CMA	Germany
Barbariol et al ¹⁵	2021	Operating Rooms and Intensive Care Units				X		CMA	Italy
Benness and Doane ¹⁶	2021	Anesthetic gases (Desflurane)	X					CMA	Australia
Bozorgi and Fahimnia ¹⁷	2021	Syringe-and-needle flu vaccine with Micro array patch-enabled thermostable flu vaccine	X		X	X		CMA	Australia
Bravo, Townsend, Tulipan and Ilyas ¹⁸	2022	Hand surgery in operating rooms				X		CMA	The USA
Burke and Stowe ¹⁹	2015	Radiography department			X			CMA	Ireland
Canadian Agency for Drugs and Technologies in Health ²⁰	2020	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	Canada
Chu et al ²¹	2021	Respirator use strategies				X		CMA	The USA
Connor et al ²²	2010	Reverse osmosis (RO) units	X	X	X			CMA	The UK
Connor et al ²³	2019	Virtual ureteric colic clinic	X					CMA	The UK
Conrardy et al ²⁴	2010	Disposable and reusable items used in surgical services				X		CMA	The USA
Craig and Wadey ²⁵	2017	Air-tight system	X			X		CMA	The UK
Crema Tobará et al ²⁶	2019	Alcohol-based solution versus scrubbing with chlorhexidine brushes		X		X		CMA	Brazil
Croghan et al ²⁷	2021	Virtual urology clinics	X					CMA	Ireland
Davie et al ²⁸	2010	Peripatetic intravenous service	X					CMA	The UK
de Preux and Rizmie ²⁹	2018	Home and in-center hemodialysis	X					CUA	The UK
Dullet et al ³⁰	2017	Telemedicine Program	X					CMA	The USA
Filfilan et al ³¹	2021	Teleconsultation in urology	X					CMA	France
Gaiser et al ³²	2004	Glass bottles on obstetric anesthesia service				X		CMA	The USA
Gatenby ³³	2011	Surgical and medical treatment of gastro-esophageal reflux	X					CMA	The UK
Hensher ³⁴	2020	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	Australia
Kocaman and Galvain ³⁵	2022	Treatment of surgical site infection	X	X		X		BIA	England
Köhler et al ³⁶	2012	UV irradiation technology			X	X		CBA	Luxembourg
Koo and Jeong ³⁷	2015	Treatment systems of medical waste				X	Photochemical oxidant creation; Acidification potential; Human toxicity potential	CMA	South Korea

continued on next page

Table 1. Continued

Authors and references	Year of publication	Healthcare products	Environment-related dimensions					Economic evaluation	Location
			CO ₂ or CO ₂ eq	Water	Energy	Waste	Other		
Kponee-Shovein et al ³⁸	2022	Inhaler choice for asthma care (DPI VS MDI)	X					CMA	England
Kwakye et al ³⁹	2011	Operating room and labor-delivery (surgery)				X		CMA	The USA
Lewis et al ⁴⁰	2009	Videoconferencing	X					CMA	The UK
Marsh et al ⁴¹	2016	Two treatment regimens: an oral antidiabetic (OAD) medication, and the addition of basal insulin therapy to this OAD regimen	X					CUA	The USA
Marsh et al ⁴²	2016	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	The UK
Masino et al ⁴³	2010	Telemedicine	X					CMA	Canada
Maughan et al ⁴⁴	2016	Social prescribing service	X					CMA	The UK
Maughan et al ⁴⁵	2016	Long-acting injections	X					CMA	The UK
Maughan et al ⁴⁶	2016	Oxfordshire therapeutic community	X					CMA	The UK
McAlister et al ⁴⁷	2021	Admissions in a Division of Medicine	X					CMA	Australia
McCarthy et al ⁴⁸	2014	Radiology department	X		X			CMA	Ireland
McGain et al ⁴⁹	2012	Reusable and single-use central venous catheter insertion kits	X	X	X	X		CMA	Australia
McGain et al ⁵⁰	2010	Reusable and single-use plastic anesthetic drug trays	X	X				CMA	Australia
McGain et al ⁵¹	2016	Hospital steam sterilizer	X	X	X			CMA	Australia
McGain et al ⁵²	2017	Reusable and single-use anesthetic equipment	X	X			Eutrophication; Human, terrestrial, and marine ecotoxicity.	CMA	Australia
Miah et al ⁵³	2019	Virtual urology clinic	X					CMA	The UK
Miltenburger et al ⁵⁴	2018	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	The UK
Ministry of Health of Brazil ⁵⁵	2009	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	Brazil
Murphie et al ⁵⁶	2016	Self-fill oxygen technology	X					CMA	The UK
Ortsäter et al ⁵⁷	2019	Reusable inhalers	X			X		BIA	Denmark, Iceland, Finland, Norway, Sweden, Belgium, The Netherlands and Luxembourg
Ortsäter et al ⁵⁸	2020	Reusable inhalers	X					BIA	Germany

continued on next page

Table 1. Continued

Authors and references	Year of publication	Healthcare products	Environment-related dimensions					Economic evaluation	Location
			CO ₂ or CO ₂ eq	Water	Energy	Waste	Other		
Polisena et al ⁵⁹	2018	Healthcare system and HTA	N/A	N/A	N/A	N/A	N/A	N/A	The USA; The UK; The USA and the UK; The USA, the UK, Germany and Belgium
Prasanna et al ⁶⁰	2011	Radiology department			X			CMA	The USA
Regan et al ⁶¹	2018	Medical program (reducing unnecessary biochemistry samples)	X					CMA	The UK
Rizan and Bhutta ⁶²	2022	Hybrid vs single-use instruments in laparoscopic cholecystectomy	X				Eutrophication, Ecotoxicity, Ionising radiation	CMA	England
Rizan et al ⁶³	2022	Surgical scissors	X				Fine particulate matter formation, Eutrophication (freshwater and marine), Ecotoxicity (terrestrial, freshwater, marine), Toxicity (human carcinogenic, human noncarcinogenic), Resource scarcity (mineral and fossil)	CMA	England
Rouvière et al ⁶⁴	2022	Sterile medical devices in operating rooms	X			X		CMA	France
Signorini, Brugnoli, Levaggi and Garrafa ⁶⁵	2021	Lab exams / tests	X			X		CMA	Italy
Soares et al ⁶⁶	2013	Small generators: involving microwaving, autoclave, and lime disinfection	X		X			CMA	Brazil
Sowa, Fookan, McGowan and Birch ⁶⁷	2022	Reusable instruments and disposable instruments for dental care provision		X	X	X		CMA	Australia
Starup-Hansen et al ⁶⁸	2020	Inhalers	X					CEA	The UK
Tarricone, Petraccia, Cucciniello and Ciani ⁶⁹	2022	Mobile medical apps	N/A	N/A	N/A	N/A	N/A	N/A	Italy
Tauber et al ⁷⁰	2019	Pharmaceutical Products in Cataract Surgery	X				Potential air pollutant emissions; Water-polluting potential eutrophication emissions.	CMA	The USA
ten Have et al ⁷¹	2022	Inhalers	X					BIA	The Netherlands

continued on next page

Table 1. Continued

Authors and references	Year of publication	Healthcare products	Environment-related dimensions					Economic evaluation	Location
			CO ₂ or CO ₂ eq	Water	Energy	Waste	Other		
Terlinden et al ⁷²	2013	Medical program (adding a cocooning strategy to a vaccinations schedule)	X					CUA	England and Wales
Vidal-Alaball et al ⁷³	2019	Telemedicine program	X					CMA	Spain
Wilkinson et al ⁷⁴	2019	Inhalers	X					CMA	The UK
Williams et al ⁷⁵	2022	Melanoma Surveillance	X					CMA	Australia

BIA indicates budget-impact analysis; CBA, cost-benefit analysis; CMA, cost-minimization analysis; CO₂ or CO₂ eq, carbon dioxide emissions or carbon dioxide equivalent emissions; CUA, cost-utility analysis; N/A, nonapplicable; HTA, health technology assessment; The UK, The United Kingdom; The USA, The United States of America.

tests only when deemed appropriate and measured the CO₂ emissions.⁶¹

Other ways to calculate CO₂ emissions were also proposed. Gatenby³³ used a top-down model of carbon to estimate CO₂ emissions and model the overall and mean cost of medication use in 2 treatments. Marsh et al⁴¹ used a health economic model (the IMS CORE model) to predict and compare several outcomes as costs of disease and specific complications, QALY, and total and incremental CO₂ emissions of treatments for type 2 diabetes mellitus. McAlister et al⁴⁷ used a top-down methodology input-output to calculate the CO₂ emissions and the financial costs associated with the number of pathology collections in a Division of Medicine.

A total of 4 studies (6.5%), including a literature review,⁶⁸ focused on the potential CO₂ emissions and associated reductions of switching pressurized metered-dose inhalers with nonpressurized inhalers.^{38,68,71,74} Kponee-Shovein et al³⁸ calculated the CO₂ emissions over longer term using models with alternative time horizon (50 and 10 years). They converted the emissions within each scenario into social cost of carbon (SCC) to estimate environmental costs and into DALYs to capture the health damages related to these emissions. They also calculated the annual expenses because of the use of inhalers along with a per capita cost.

Waste management

Six of the 62 (9.7%) included documents focused on waste management of healthcare products. Conrardy et al²⁴ estimated the reduction in waste as a consequence of the adoption of reusable products in place of disposable items; whereas Gaiser et al³² compared glass bottle elimination and recycling within an obstetric service.

In a literature review, Kwakye et al³⁹ focused mainly on waste reduction and cost savings associated with greener initiatives in the surgical units. Another literature review from Bravo et al¹⁸ focused on reduction in cost and waste of a new local anesthesia for hand.

Chu et al²¹ compared several respirator strategies (disposable vs reusable with or without filter) for 6 months in the context of the COVID-19 outbreak and calculated the cost and the waste generation of each strategy.

Waste is a broad concept which encompasses drug wastage. Barbariol et al¹⁵ measured the amount of drug wastage (medical materials and unused drugs) in 2 medical services. They also estimated the weight of preventable medical waste and the associated financial cost.

Energy consumption

Two of the 62 (3.2%) included documents focused on energy consumption of different devices (desktop, workstation displays, and ancillary electrical equipment) in radiology departments.^{19,60} Burke and Stowe¹⁹ estimated potential energy and cost savings associated with powered off devices when department closed. While Prasanna et al⁶⁰ calculated energy and cost savings when medical equipments were turned off after an 8-hour workday.


Multienvironment-related dimensions

Almost a third (n = 20) of the included documents looked at several environment-related spillovers at the same time.

Three articles considered both waste disposal and energy consumption.^{12,64,65} Adler et al¹⁴ conducted a literature review into green cost savings initiatives in surgical services. Köhler et al³⁶ measured energy efficiency and pharmaceutical removal from wastewater of an UV irradiation technology using the LCA methodology and a cost-benefit analysis. In their study on the use of disposable versus reusable instruments in dental health practice, Sowa et al⁶⁷ used a costing model to estimate the costs at the microlevel (day-to-day) and the macro level (organization level) in 3 situations: current situation, use of reusable, and use of disposable items. They estimated the environmental impacts of waste, water, and energy consumption in these 3 situations.

Crema Tobara et al²⁶ estimated waste volume, water consumption, and cost savings of using alcohol solution to disinfect surgeons' hands instead of chlorhexidine brushes.

A set of publications (16.1%, n = 10) investigated both CO₂ emissions along with other environmental dimensions.^{17,22,25,35,48-51,65,66} Bozorgi and Fahimnia¹⁷ undertook a cost analysis to replace syringe-and-needle flu vaccine with microarray patch-enabled thermostable flu vaccine; they also presented benefits of this change, including the environmental benefits (reductions in energy and fuel consumption, CO₂ emissions, and waste generation). McCarthy et al⁴⁸ converted the energy consumption of medical equipment in the radiology department into CO₂ emissions, and they calculated the financial cost of the electricity use. Craig and Wadey²⁵ estimated the carbon footprint, waste disposable, and costs savings of an air-tight waste disposal system. Kocaman and Galvain³⁵ in a conference abstract presented their study on the environmental impacts (CO₂, water use, and waste generation) of treating surgical site infection at the hospital and calculated the cost of the treatment. Two different studies by McGain et al^{49,50} calculated both CO₂ emissions, water consumption, and costs of reusable and disposal healthcare products such as

Figure 2. Temporal distribution of the included documents.

central venous catheter kits and anesthetic drug trays. They also estimated energy consumption related to central venous catheter kits.⁴⁹ In a third study, McGain et al⁵¹ tested 2 policies of switching off sterilizers at different moments and estimated CO₂ emissions reductions, water and electricity savings related to each policy. Nevertheless, cost savings were only calculated for electricity and water. Signorini et al⁶⁵ compared the demand for COVID19 lab tests with the recommendations of the Internal Federation of Clinical Chemistry guidelines and the literature. They estimated the economic costs and ecological (CO₂ equivalent and waste emissions) impacts of these tests and emphasized ecological and environmental benefits when tests are done only when necessary. Soares et al⁶⁶ used the LCA method to calculate electricity and gas consumptions; and costs of 3 small generators (microwaving, autoclaving, and lime disinfection) employed for waste management.

Few articles (9.7%, $n = 6$) calculated the environmental impacts of healthcare devices (reusable and single anesthetic equipment⁵² or single-use versus hybrid instruments⁶²) or healthcare practices (treatment systems of medical waste,³⁷ repairing surgical scissors strategies,⁶³ implementation of sustainable measure targeting sterile medical devices in operating room⁶⁴ or unused pharmaceutical products in cataract surgery⁷⁰) and classified them into various categories such as global warming (specially CO₂); eutrophication; human, terrestrial, and marine ecotoxicity, etc. LCA was used in 4 articles^{52,62-64} to estimate the environmental spillovers. Each article determined the direct cost of the assessed healthcare products: 1 by a net cost analysis,³⁷ 1 by a Monte Carlo analysis,⁵² 2 by life cycle cost analysis,^{62,63} 1 using a bottom-up microcosting methodology,⁶⁴ and the last 1 used an economic input-output LCA model.⁷⁰

Integrative Approach

The articles relevant to the integrative approach ($n = 11$) can be divided in 2 groups whether they provide practical or theoretical

ways to integrate environment-related concerns in economic evaluation.

Practical solutions

A total of 4 studies (6.5%) undertook a full economic evaluation of healthcare products (use of home vs in-center hemodialysis,²⁹ use of reusable inhalers,^{57,58} and implementation of a medical program⁷²) and included CO₂ emissions in the evaluation.^{29,57,58,72} They calculated CO₂ emissions and then converted these emissions into monetary costs such as the SCC^{29,57,58} or the carbon cost.⁷² De Preux and Rizmie²⁹ and Terlinden et al⁷² included this monetary value in the calculation of the incremental cost-effectiveness ratio, while Ortsäter et al^{57,58} included the SCC into a budget-impact analysis over a 5-year time period perspective.

Theoretical solutions

Three documents (4.8%) including a conference abstract,^{34,42,54} discussed methods to consider the environmental impacts of healthcare systems in economic evaluation. Marsh et al⁴² and Miltenburg et al⁵⁴ proposed to convert CO₂ emissions into monetary units such as SCC to include environment-related dimensions into cost-benefit analysis or budget-impact analysis. According to Marsh et al,⁴² environmental dimensions transformed into health outcomes could be used in cost-utility analysis. The authors also suggested to utilize multicriteria decision analysis to include environment-related spillovers.⁴² In his article, Hensher³⁴ already recommended to consider negative externalities of healthcare systems by using finding from ecological economics.³²

Polisena et al⁵⁹ conducted a scoping review to identify existing frameworks, methods and case studies about the assessment of environmental impact of health technologies and included evidence with different foci: health economics, engineering practices, and the ecosystem. In an article on lifecycle, multidimensional

Table 2. Summary of the assessed healthcare interventions.

Healthcare products or interventions or technologies	Environment-related spillovers
Anesthetic gases	CO ₂
Virtual clinics	
Peripatetic intravenous service	
Home and in-center hemodialysis	
Telemedicine programs	
Teleconsultation in urology	
Surgical and medical treatment of gastro-esophageal reflux	
Two treatments for type-2 diabetes	
Social prescribing service	
Long-acting injections	
Oxfordshire therapeutic community	
Admissions in a Division of Medicine	
Self-fill oxygen technology	
Medical programs	
Surgical scissors	
Pharmaceutical Products in Cataract Surgery	
Melanoma Surveillance	
Operating Rooms and Intensive Care Units	Waste
Hand surgery in operating rooms	
Respirator use strategies	
Glass bottles on obstetric anesthesia service	
Treatment systems of medical waste	
Operating room and labor-delivery (surgery)	
Alcohol-based solution versus scrubbing with chlorhexidine brushes	Waste and water
UV irradiation technology	Waste and energy
Radiology department	CO ₂ and energy
Small generators: involving microwaving, autoclave, and lime disinfection	CO ₂ and energy
Inhalers	CO ₂ and waste
Sterile medical devices in operating rooms	
Laboratory examinations/tests	
Air-tight system	
Syringe-and-needle flu vaccine with micro array patch-enabled thermostable flu vaccine	CO ₂ , waste and energy
Reusable and single-use items	
Hospital steam sterilizer	CO ₂ , energy and water
Reverse osmosis (RO) units	
Treatment of surgical site infection	CO ₂ , waste and water

CO₂ indicates carbon dioxide or carbon dioxide equivalent emissions; energy, energy consumption; waste, waste management; water, water consumption.

assessment framework assessment of mobile medical apps, Taricone et al⁶⁹ suggested to conduct an economic evaluation and to consider environmental impact as an additional outcome. Nevertheless, they did not provide any suggestion on how to do so and did not include the environmental assessment as a component of the economic evaluation.


While the Brazilian and Canadian health agencies^{20,55} included environmental impact as a relevant criterion in their economic evaluation guidelines, they did not provide any recommendation on how environmental spillovers should be appraised.

Discussion

This scoping review is the first attempt at studying whether the environment-related dimensions of healthcare products are

included within economic evaluations. Around 30% of the included documents were published in the year 2021 and 2022. This underlines the increased awareness of environmental spillovers of healthcare systems. The majority of studies were based in the UK; this is not surprising since the National Health Service supports initiatives for greener and sustainable healthcare interventions.⁷⁶

This review reveals that there are a number of initiatives to assess both the environmental effects and costs of healthcare products and to extend HTAs to including environment-related concerns. It also highlights that health agencies such as the Brazilian and Canadian health agencies have started to consider environment-related dimensions as a criterion within the HTA process. Still, guidance on which environmental data to include in economic evaluations and standardized methods on how to assess these environmental effects within the HTA process are lacking.

Figure 3. Percentage of each investigated environment-related spillover.

CO₂ indicates carbon dioxide.

The included publications in this scoping review differed in their ways to assess environment-related dimensions of healthcare products. The most common approach was the LCA. This method is not specific to the healthcare system but seems to be an effective alternative. Indeed, the authors who used it were able to estimate the magnitude of environmental spillovers of healthcare products. Healthcare systems are not subject to environmental standards, therefore there is no guidance on how to evaluate environment-related dimensions. Even the documents which recommended to assess the environmental impact of healthcare technologies, gave no information on how to do so.

This review highlights that CO₂ emissions were the most assessed environmental dimension. It is not clear whether other environmental dimensions were not assessed because of the complexity of estimating these effects, or because CO₂ emissions have a higher priority compared with other environmental concerns.

Only 4 documents provided solutions to including environmental impacts in the calculation of the incremental cost-effectiveness ratio within a cost-utility analysis by converting CO₂ emissions into monetary values. One study converted CO₂ emissions into DALYs but did not include it in an economic evaluation.³⁸ It appears therefore possible to convert environmental spillovers alternatively as a health benefit or as a cost.

Recommendations

This review highlighted a number of issues that should be clarified if environmental spillovers are included in the HTA process. Researchers must first be guided on (1) which environmental spillovers to include, (2) how environmental spillovers should be measured, especially whether they should be included as a health-related or as cost-related to avoid any

double counting, and (3) finally whether environmental spillovers should form a sensitivity analysis scenario or belong to the base case scenario. The inclusion of environment-related spillovers in the HTA process will also lead to trade-offs between the efficiency of an intervention and its environmental impact. It might happen that achieving better environmental impact led to higher costs and therefore, a lower cost-effectiveness. A simple way to deal with these trade-offs could be to take inspiration from other perspectives such as the equity-efficiency trade-offs in HTA.^{77,78}

In line with National Institute for Health and Care Excellence⁷⁹ and the Canada's Drug and Health Technology Agency,⁸⁰ which are in the process of establishing a list of criteria to guide the incorporation of environment-related dimensions into the decision-making process, international guidelines on which environment-related dimensions to assess and how to deal with environment-related data in economic evaluation, should be developed in the near future. It is recommended that international networks on HTA and their health agencies should collaborate to develop a joint reference case to assist in the inclusion of environmental effects in HTA.

More globally, to reduce the environment-related spillovers of the health sector, governments should implement circular economy policies in healthcare. This transition requires actions such as "recycling; reuse of products; prevention of waste; and a shift in consumption patterns"⁸¹ but also changes in "perception and behavior from consumers to producers."⁸¹

Limitations

We may have missed some sources in this review for 3 reasons. First, this review was limited to documents available in English or French. Second, it only focused on EU-12 and G20 countries;

however, we can reasonably assume that if we included low-and middle-income countries, we would have found similar results since the inclusion of environmental aspects remains limited internationally and health agencies are mainly developed in high-income countries. Finally, searches only focused on the 3 major medical databases and publications available on other databases as well as gray literature was not considered.

Conclusions

Sustainable and green practices in the healthcare sector have gained more interest in recent years. This review adds to the existing work on the inclusion of environmental spillovers in economic evaluations. This research highlighted a number of publications considering both the environmental spillovers of healthcare products and undertaking cost-minimization analyses. The lack of methods on how to assess environmental dimensions, which dimensions to assess and how to integrate environmental data in economic evaluations, lead to a vast heterogeneity in the methodologies. The commitment of international health agencies for sustainable healthcare is likely to lead to the development of a standardized framework to guide the inclusion of environment-related dimensions in the decision-making process.

Supplemental Material

Supplementary data associated with this article can be found in the online version at <https://doi.org/10.1016/j.jval.2023.03.008>.

Article and Author Information

Accepted for Publication: March 15, 2023

Published Online: xxxx

doi: <https://doi.org/10.1016/j.jval.2023.03.008>

Author Affiliations: Institute of Health and Society (IRSS), Université Catholique de Louvain (UCLouvain), Brussels, Belgium (Desterbecq, Tubeuf); Institute of Economic and Social Research (IRES), Université Catholique de Louvain (UCLouvain), Brussels, Belgium (Tubeuf).

Correspondence: Charlotte Desterbecq, MPH, Institute of Health and Society (IRSS), Université Catholique de Louvain (UCLouvain), Brussels, Belgium. Email: charlotte.desterbecq@uclouvain.be

Author Contributions: *Concept and design:* Desterbecq, Tubeuf
Acquisition of data: Desterbecq
Analysis and interpretation of data: Desterbecq
Drafting of the article: Desterbecq, Tubeuf
Critical revision of the article for important intellectual content: Desterbecq, Tubeuf
Supervision: Desterbecq, Tubeuf

Conflict of Interest Disclosures: The authors reported no conflicts of interest.

Funding/Support: The authors received no financial support for this research.

Acknowledgment: The authors acknowledge the help of Clément Beghuin and Roxane Mousset in the analysis process. The authors also thank Martin Hensher, Laure de Preux, Liza Sopina, colleagues from Economics Health Inequalities at Louvain, and the members of Charlotte's doctoral steering committee for their helpful comments on previous versions of this article. The authors finally thank attendees to the 2022 EuHEA conference in Galway, the IRSS Seminars, and the 2022 UCLouvain interdisciplinary conference where this article was presented.

REFERENCES

1. Closos MC, Marchand M. For sustainable health development. *Reflète Perspect Vie Econ*. 2002;1:65–74.
2. Fast facts on climate and health. World Health Organization. <https://www.who.int/publications/m/item/fast-facts-on-climate-change-and-health>. Accessed November 1, 2021.
3. Weillhammer V, Schmid J, Mittermeier I, et al. Extreme weather events in Europe and their health consequences – a systematic review. *Int J Hyg Environ Health*. 2021;233:113688.
4. Eckelman MJ, Sherman JD. Estimated global disease burden from US health care sector greenhouse gas emissions. *Am J Public Health*. 2018;108(S2):S120–S122.
5. Climate Change 2022: Impacts, Adaptation and Vulnerability. Reliefweb. https://reliefweb.int/report/world/climate-change-2022-impacts-adaptation-and-vulnerability?gclid=Cj0KCQjw2v-gBhC1ARISAOQdKY3AaSk6d60swaUwUwOeb5vMfMK2H-KQcj14Gr-ZUklb1mYkwtRIRQaAkuWEALw_wcB. Accessed April 1, 2022.
6. COP26 Health Programme. World Health Organization. <https://www.who.int/initiatives/alliance-for-transformative-action-on-climate-and-health/cop26-health-programme>. Accessed February 28, 2022.
7. Romanello M, McGushin A, Di Napoli C, et al. The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future. *Lancet*. 2021;398(10311):1619–1662.
8. Francetic I, Meacock R, Elliott J, et al. Framework for identification and measurement of spillover effects in policy implementation: intended non-intended targeted non-targeted spillovers (INTENTS). *Implement Sci Commun*. 2022;3(1):30.
9. Osipenko L, Gajraj E. NICE guidance and health technology assessment. In: Thomas D, ed. *Clinical Pharmacy Education, Practice and Research: Clinical Pharmacy, Drug Information, Pharmacovigilance, Pharmacoeconomics and Clinical Research*. Amsterdam, The Netherlands: Elsevier; 2019:313–320.
10. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford, United Kingdom: Oxford University Press; 2015.
11. Williams A. The economic role of health indicators. *Meas Soc Benefit Med*. 1983;63–67.
12. Birch S, Donaldson C. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism? *Soc Sci Med*. 2003;56(5):1121–1133.
13. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF. Welfarism vs. extra-welfarism. *J Health Econ*. 2008;27(2):325–338.
14. Adler S, Scherrer M, Rückauer KD, Daschner FD. Comparison of economic and environmental impacts between disposable and reusable instruments used for laparoscopic cholecystectomy. *Surg Endosc*. 2005;19(2):268–272.
15. Barbario F, Deana C, Lucchese F, et al. Evaluation of drug wastage in the operating rooms and intensive care units of a regional health service. *Anesth Analg*. 2021;132(5):1450–1456.
16. Benness M, Doane M. Anaesthetists are primed to leap into action on climate change. *Anaesthesiol Intensive Care*. 2021;49(2):7–8.
17. Bozorgi A, Fahimnia B. Micro array patch (MAP) for the delivery of thermo-stable vaccines in Australia: A cost/benefit analysis. *Vaccine*. 2021;39(41):6166–6173.
18. Bravo D, Townsend CB, Tulipan J, Ilyas AM. Economic and environmental impacts of the wide-awake, local anesthesia, no tourniquet (WALANT) technique in hand surgery: a review of the literature. *J Hand Surg Glob Online*. 2022;4(2):456–463.
19. Burke NP, Stowe J. Energy efficiency in the radiography department: an Irish perspective. *Radiography*. 2015;21(2):150–153.
20. Overview of HTA and OU medical devices and clinical interventions. Canadian Agency for Drugs and Technologies in Health. <https://www.cadth.ca/sites/default/files/attachments/2022-11/Overview%20of%20HTA%20and%20OU%20Medical%20Devices%20and%20Clinical%20Interventions.pdf>. Accessed May 1, 2022.
21. Chu J, Ghenand O, Collins J, et al. Thinking green: modelling respirator reuse strategies to reduce cost and waste. *BMJ Open*. 2021;11(7):e048687.
22. Connor A, Milne S, Owen A, Boyle G, Mortimer F, Stevens P. Toward greener dialysis: a case study to illustrate and encourage the salvage of reject water. *J Ren Care*. 2010;36(2):68–72.
23. Connor MJ, Miah S, Edison MA, et al. Clinical, fiscal and environmental benefits of a specialist-led virtual ureteric colic clinic: a prospective study. *BJU Int*. 2019;124(6):1034–1039.
24. Conrardy J, Hillanbrand M, Myers S, Nussbaum GF. Reducing medical waste. *AORN J*. 2010;91(6):711–721.
25. Craig G, Wadey C. Safe disposal of cytotoxic waste: an evaluation of an airtight system. *Brit J Nurs*. 2017;26(16):S18–S24.
26. Crema Tobara M, De Almeida Silva C, Martins Silva P, et al. Success in implantation of surgical hands disinfection with alcohol solution: impact on cost and environmental resources. *Antimicrob Resist Infect Control*. 2019;8.
27. Croghan S, Rohan P, Considine S, et al. Time, cost and carbon-efficiency: a silver lining of COVID era virtual urology clinics? *Ann R Coll Surg Engl*. 2021;103(8):599–603.

28. Davie M, Jeffreson P, Jones T, Roberts T, Adekunle F, Mitchell P. Peripartetic intravenous service for metabolic bone disease: case study in patient centred-care for new NHS. *Curr Med Res Opin.* 2010;26(8):2033–2039.
29. de Preux L, Rizmie D. Beyond financial efficiency to support environmental sustainability in economic evaluations. *Future Health J.* 2018;5(2):103–107.
30. Dullet NW, Geraghty EM, Kaufman T, et al. Impact of a university-based outpatient telemedicine program on time savings, travel costs, and environmental pollutants. *Value Health.* 2017;20(4):542–546.
31. Filfilan A, Anract J, Chartier-Kastler E, et al. Positive environmental impact of remote teleconsultation in urology during the COVID-19 pandemic in a highly populated area. *Prog Urol.* 2021;31(16):1133–1138.
32. Gaier RR, Cheek TG, Gutsche BB. Glass recycling in the labour suite is environmentally sound and economical. *Br J Anaesth.* 2004;92(4):584–586.
33. Gatenby PAC. Modelling the carbon footprint of reflux control. *Int J Surg.* 2011;9(1):72–74.
34. Hensher M. Incorporating environmental impacts into the economic evaluation of health care systems: perspectives from ecological economics. *Resour Conserv Recycl.* 2020;154:1–12.
35. Kocaman M, Galvain T, POSA113 The cost analysis of the environmental impacts of surgical site infection from the perspective of NHS England. *Value Health.* 2022;25(1):S55.
36. Köhler C, Venditti S, Igos E, Klepiszewski K, Benetto E, Cornelissen A. Elimination of pharmaceutical residues in biologically pre-treated hospital wastewater using advanced UV irradiation technology: a comparative assessment. *J Hazard Mater.* 2012;239–240:70–77.
37. Koo JK, Jeong SI. Sustainability and shared smart and mutual - green growth (SSaM-GG) in Korean medical waste management. *Waste Manag Res.* 2015;33(5):410–418.
38. Kponee-Shovein K, Marvel J, Ishikawa R, et al. Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation. *J Med Econ.* 2022;25(1):940–953.
39. Kwakye G, Brat GA, Makary MA. Green surgical practices for health care. *Arch Surg.* 2011;146(2):131–136.
40. Lewis D, Tranter G, Axford AT. Use of videoconferencing in Wales to reduce carbon dioxide emissions, travel costs and time. *J Telemed Telecare.* 2009;15(3):137–138.
41. Marsh K, Ganz M, Nortoft E, Lund N, Graff-Zivin J. Incorporating environmental outcomes into a health economic model. *Int J Technol Assess Health Care.* 2016;32(6):400–406.
42. Marsh K, Ganz ML, Hsu J, Strandberg-Larsen M, Gonzalez RP, Lund N. Expanding health technology assessments to include effects on the environment. *Value Health.* 2016;19(2):249–254.
43. Masino C, Rubinstein E, Lem L, Purdy B, Rossos PG. The impact of telemedicine on greenhouse gas emissions at an academic health science center in Canada. *Telemed J Health.* 2010;16(9):973–976.
44. Maughan DL, Patel A, Parveen T, et al. Primary-care-based social prescribing for mental health: an analysis of financial and environmental sustainability. *Prim Health Care Res Dev.* 2016;17(2):114–121.
45. Maughan DL, Lillywhite R, Cooke M. Cost and carbon burden of long-acting injections: a sustainable evaluation. *BJPsych Bull.* 2016;40(3):132–136.
46. Maughan D, Lillywhite R, Pearce S, Pillinger T, Weich S. Evaluating sustainability: a retrospective cohort analysis of the Oxfordshire therapeutic community. *BMC Psychiatry.* 2016;16(1):285.
47. McAlister S, Smyth B, Koprivic I, et al. Carbon emissions and hospital pathology stewardship: a retrospective cohort analysis [published online November 15, 2021]. *Int Med J.* <https://doi.org/10.1111/imj.15622>.
48. McCarthy CJ, Gerstenmaier JF, O'Neill AC, McEvoy SH, Hegarty C, Heffernan EJ. "EcoRadiology"—pulling the plug on wasted energy in the radiology department. *Acad Radiol.* 2014;21(12):1563–1566.
49. McGain F, McAlister S, McGavin A, Story D. A life cycle assessment of reusable and single-use central venous catheter insertion kits. *Anesth Analg.* 2012;114(5):1073–1080.
50. McGain F, McAlister S, McGavin A, Story D. The financial and environmental costs of reusable and single-use plastic anaesthetic drug trays. *Anaesthesiol Intensive Care.* 2010;38(3):538–544.
51. McGain F, Moore G, Black J. Hospital steam sterilizer usage: could we switch off to save electricity and water? *J Health Serv Res Policy.* 2016;21(3):166–171.
52. McGain F, Story D, Lim T, McAlister S. Financial and environmental costs of reusable and single-use anaesthetic equipment. *Br J Anaesth.* 2017;118(6):862–869.
53. Miah S, Dunford C, Edison M, et al. A prospective clinical, cost and environmental analysis of a clinician-led virtual urology clinic. *Ann R Coll Surg Engl.* 2019;101(1):30–34.
54. Miltenburger C, Borgstrom F, Eklund O. Ecological benefits of health technologies - how to consider public value in funding decisions? *Value Health.* 2018;21:S25.
55. Methodological guidelines : health technology assessment appraisals. Ministry of Health of Brazil. https://bvsms.saude.gov.br/bvs/publicacoes/methodological_guidelines_technology_assessment_appraisals.pdf. Accessed May 1, 2022.
56. Murphie P, Hex N, Setters J, Little S. Self-fill oxygen technology: benefits for patients, healthcare providers and the environment. *Breathe (Sheff).* 2016;12(2):113–119.
57. Ortsäter G, Borgström F, Soulard S, Miltenburger C. A budget impact model to estimate the environmental impact of adopting RESPIMAT® re-usable in the Nordics and Benelux. *Adv Ther.* 2019;36(12):3435–3445.
58. Ortsäter G, Borgström F, Baldwin M, Miltenburger C. Incorporating the environmental impact into a budget impact analysis: the example of adopting RESPIMAT® re-usable inhaler. *Appl Health Econ Health Policy.* 2020;18(3):433–442.
59. Polisen J, De Angelis G, Kaunelis D, Gutierrez-Ibarluzea I. Environmental impact assessment of a health technology: a scoping review. *Int J Technol Assess Health Care.* 2018;34(3):317–326.
60. Prasanna PM, Siegel E, Kunc A. Greening radiology. *J Am Coll Radiol.* 2011;8(11):780–784.
61. Regan W, Hothi D, Jones K. Sustainable approach to reducing unnecessary combined biochemistry tests on a paediatric cardiology ward. *BMJ Open Qual.* 2018;7(4):e000372.
62. Rizan C, Bhutta MF. Environmental impact and life-cycle financial cost of hybrid (reusable/single-use) instruments versus single-use equivalents in laparoscopic cholecystectomy. *Surg Endosc.* 2022;36(6):4067–4078.
63. Rizan C, Brophy T, Lillywhite R, Reed M, Bhutta MF. Life cycle assessment and life cycle cost of repairing surgical scissors. *Int J Life Cycle Assess.* 2022;27(6):780–795.
64. Rouvière N, Chkair S, Auger F, et al. Ecoresponsible actions in operating rooms: a health ecological and economic evaluation. *Int J Surg.* 2022;101:106637.
65. Signorini SG, Brugnoli D, Levaggi R, Garrafa E. Less is more: an ecological and economic point of view on appropriate use of lab testing for COVID-19 patients. *Bioanalysis.* 2021;13(24):1781–1783.
66. Soares SR, Finotti AR, da Silva VP, Alvarenga RA. Applications of life cycle assessment and cost analysis in health care waste management. *Waste Manag.* 2013;33(1):175–183.
67. Sowa PM, Fookien J, McGowan K, Birch S. Disposable and reusable instruments in dental health practice: A comparison of cost factors in a public provider organization in Queensland, Australia [published online June 5, 2022]. *Community Dent Oral Epidemiol.* <https://doi.org/10.1111/cdoe.12764>.
68. Starup-Hansen J, Dunne H, Sadler J, Jones A, Okorie M. Climate change in healthcare: exploring the potential role of inhaler prescribing. *Pharmacol Res Perspect.* 2020;8(6):e00675.
69. Tarricone R, Petracca F, Cucciniello M, Ciani O. Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. *Health Econ.* 2022;31(suppl 1):73–97.
70. Tauber J, Chinwuba I, Kleyn D, Rothschild M, Kahn J, Thiel CL. Quantification of the cost and potential environmental effects of unused pharmaceutical products in cataract surgery. *JAMA Ophthalmol.* 2019;137(10):1156–1163.
71. Ten Have P, Van Hal P, Wichers I, et al. Turning green: the impact of changing to more eco-friendly respiratory healthcare-a carbon and cost analysis of Dutch prescription data. *BMJ Open.* 2022;12(6):e055546.
72. Terlinden A, Renson B, Ponder C, Poirrier JE, Curran D. Carbon cost-effectiveness of cocooning immunization against pertussis in England and Wales: an ecological perspective. *Value Health.* 2013;16(7):A578.
73. Vidal-Alaball J, Franch-Parella J, Seguí FL, Cuyàs FG, Peña JM. Impact of a telemedicine program on the reduction in the emission of atmospheric pollutants and journeys by road. *Int J Environ Res Public Health.* 2019;16(22):4366.
74. Wilkinson AJ, Braggins R, Steinbach I, Smith J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. *BMJ Open.* 2019;9(10):e028763.
75. Williams JTW, Bell KJL, Morton RL, Dieng M. Exploring the integration of environmental impacts in the cost analysis of the pilot MEL-SELF trial of patient-led melanoma surveillance. *Appl Health Econ Health Policy.* 2023;21(1):23–30.
76. Delivering a "Net Zero" National Health Service. NHS England. <https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2020/10/delivering-a-net-zero-national-health-service.pdf>. Accessed September 1, 2022.
77. Benkhalti M, Espinoza M, Cookson R, Welch V, Tugwell P, Dagenais P. Development of a checklist to guide equity considerations in health technology assessment. *Int J Technol Assess Health Care.* 2021;37:e17.
78. Williams AH, Cookson RA. Equity-efficiency trade-offs in health technology assessment. *Int J Technol Assess Health Care.* 2006;22(1):1–9.
79. Sustainability. National Institute for Health and Care Excellence. <https://www.nice.org.uk/about/who-we-are/sustainability>. Accessed April 1, 2022.
80. Criteria for Conducting Environmental Assessments in CADTH HTAs. Canadian Agency for Drugs and Technologies in Health. <https://www.cadth.ca/criteria-conducting-environmental-assessments-cadth-hwas>. Accessed April 1, 2022.
81. Circular economy and health: opportunities and risks. World Health Organization. Regional Office for Europe. <https://apps.who.int/iris/handle/10665/342218>. Accessed January 1, 2023.